natgillin/translations-raw huggingface dataset:
Herceptin and anthracyclines should not be given concurrently in the adjuvant treatment setting.
Pri adjuvantnem zdravljenju raka dojk zdravila Herceptin in antraciklinov ne smemo dajati sočasno.
Do not administer as an intravenous push or bolus.
Zdravila ne smemo dajati kot hitro intravensko infuzijo ali bolus.
As Herceptin does not contain any antimicrobial-preservative, from a microbiological point of view, the medicine should be used immediately.
Z mikrobiološkega stališča je zdravilo Herceptin treba uporabiti takoj, saj ne vsebuje konzervansov.
Disease-free survival No. patients with event p<0.0001
Preživetje brez bolezni: število bolnikov z dogodkom p < 0,0001
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Herceptin 150 mg powder for concentrate
IME ZDRAVILA IN POT(I) UPORABE Herceptin 150 mg prašek za koncentrat trastuzumab le za intravensko uporabo
In this trial, 2 cohorts (one using subcutaneous formulation in vial and one using subcutaneous formulation in administration system) were investigated using a 2-arm, cross-over design with 488 patients being randomized to one of two different three-weekly Herceptin treatment sequences (IV [Cycles 1-4]→ SC [Cycles 5-8], or SC [Cycles 1-4]→ IV [Cycles 5-8]).
Šlo je za navzkrižno zasnovano preskušanje z dvema skupinama, v katerem so 488 bolnikov randomizirali v prejemanje enega od dveh različnih 3-tedenskih zaporedij zdravljenja z zdravilom Herceptin (iv. [1. do
• respiratory distress
· okužba pljuč
MBC
AGC
(57.8 µg/mL) of the study.
(5. do 8. cikel).
In patients with lower body weights (<59 kg, the lowest body weight quartile) the fixed dose used in the Herceptin subcutaneous arm was not associated with an increased risk of cardiac events or significant drop in LVEF.
Herceptin, ni bil povezan z višjim tveganjem za neželene učinke, povezane s srcem, ali pomembnim padcem v LVEF.
Distant disease-free survival
Preživetje brez bolezni
- following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.
se zdravilo Herceptin daje sočasno s paklitakselom po kemoterapiji z doksorubicinom in ciklofosfamidom.
No staining is observed or membrane staining is observed in < 10 % of the tumour cells
Obarvanje ni prisotno ali pa so obarvane membrane pri < 10 % vseh tumorskih celic v preparatu.
The recommended maintenance dose at three-weekly intervals is 6 mg/kg body weight, beginning three weeks after the loading dose.
Priporočen vzdrževalni odmerek je 6 mg/kg telesne mase po 3 tednih od prejema uvajalnega odmerka, in nato v tritedenskih razmakih.
No. patients with event p=0.0182
Smrt (dogodek celokupnega preživetja): število bolnikov z dogodkom p = 0,0182
• headache
· hemoroidi
In addition a post-hoc exploratory analysis was performed on the data sets from the joint analysis (JA) NSABP B-31/NCCTG N9831* and BCIRG006 clinical studies combining DFS events and symptomatic cardiac events and summarised in Table 10: Table 10: Post-hoc exploratory analysis results from the joint analysis NSABP B-31/NCCTG N9831*
Dodatno so izvedli post-hoc eksplorativno analizo podatkov iz skupne analize kliničnih študij NSABP B-31/NCCTG N9831 in BCIRG006, ki vključujejo dogodke preživetja brez bolezni in simptomatske srčne dogodke.
Table 5 Efficacy Results from the Non-Comparative Monotherapy and Combination Therapy Studies Parameter
Preglednica 5 navaja rezultate učinkovitosti monoterapije in kombiniranega zdravljenja iz študij brez primerjalne skupine.
A weak to moderate complete membrane staining is detected in > 10 % of the tumour cells.
Šibko do srednje močno obarvane celotne membrane pri > 10 % tumorskih celic.
1Cardiac flutter
1nereden srčni utrip
Herceptin intravenous formulation is not for subcutaneous use and should be given as an intravenous infusion only.
Intravenska oblika zdravila Herceptin ni namenjena subkutani aplikaciji in se lahko daje le z intravensko infuzijo.
Herceptin subcutaneous fixed dose formulation is not for intravenous use and should be given as a subcutaneous injection only.
Subkutana oblika zdravila Herceptin ni namenjena intravenski aplikaciji in se lahko daje le s subkutano injekcijo.
In the neoadjuvant-adjuvant treatment setting, study MO16432, a multicentre randomised trial, was designed to investigate the clinical efficacy of concurrent administration of Herceptin with neoadjuvant chemotherapy including both an anthracycline and a taxane, followed by adjuvant Herceptin, up to a total treatment duration of 1 year.
Pri adjuvantnem zdravljenju so zdravilo Herceptin proučevali v 4 obsežnih, multicentričnih, randomiziranih preskušanjih: - Študija BO16348 je bila zasnovana za primerjavo enoletnega in dvoletnega zdravljenja z zdravilom Herceptin (odmerjanjem na 3 tedne) z opazovanjem bolnikov z zgodnjo obliko HER2-pozitivnega raka dojk po operaciji, standardni kemoterapiji in radioterapiji (kar so uporabili).
STATEMENT OF ACTIVE SUBSTANCE(S) The vial contains 150 mg trastuzumab.
Viala vsebuje 150 mg trastuzumaba.
The difference in serious adverse event rates between formulations was mainly due to infections with or without neutropenia (4.4 % versus 8.1 %) and cardiac disorders (0.7 % versus 1.7 %);
Razlika v pogostnosti resnih neželenih učinkov med oblikama je bila v glavnem zaradi okužb z nevtropenijo ali brez nje (4,4 % v primerjavi z 8,1 %) in srčnimi dogodki (0,7 % v primerjavi z 1,7 %); · pooperativne okužbe rane (hude in/ali resne): 1,7 % za intravensko obliko v primerjavi s 3,0 % za subkutano obliko; · z aplikacijo povezane reakcije med obdobjem zdravljenja: 37,2 % za intravensko obliko v primerjavi s 47,8 % za subkutano obliko; · hipertenzija: 4,7 % za intravensko obliko v primerjavi z 9,8 % za subkutano obliko.
Uncommon side effects of Herceptin: may affect up to 1 in 100 people
Občasni neželeni učinki zdravila Herceptin, ki se lahko pojavijo pri največ 1 od 100 bolnikov, so: · gluhost
L-histidine hydrochloride monohydrate L-histidine α,α-trehalose dihydrate polysorbate 20
L-histidin a,a-trehaloza dihidrat polisorbat 20
Switching treatment between Herceptin intravenous and Herceptin subcutaneous formulations and vice versa, using the three-weekly (q3w) dosing regimen, was investigated in study MO22982 (see section 4.8).
V študiji MO22982 so proučevali prehod z zdravljenja z zdravilom Herceptin v intravenski obliki na subkutani obliki in obratno s 3-tedenskim režimom odmerjanja (glejte poglavje 4.8).
AC→D = doxorubicin plus cyclophosphamide, followed by docetaxel; AC→DH = doxorubicin plus cyclophosphamide, followed by docetaxel plus trastuzumab; CI = confidence interval Table 9: Overview of efficacy analyses BCIRG 006 AC→D versus DCarbH
AC → D = doksorubicin in ciklofosfamid, ki jima sledi docetaksel; DCarbH = docetaksel, karboplatin in trastuzumab; IZ = interval zaupanja V študiji BCIRG 006 se razmerje ogroženosti za primarni cilj, preživetje brez bolezni, izraža kot absolutna korist skupine AC → DH (zdravilo Herceptin) v smislu 3-letnega preživetja brez bolezni za
The addition of Herceptin to paclitaxel chemotherapy also resulted in a 37 % decrease in the risk of death.
Hkrati je zmanjšal tudi tveganje za smrt za 37 %.
In the BCIRG 006 study Herceptin was administered either in combination with docetaxel, following
V študiji BCIRG 006 so zdravilo Herceptin dajali v kombinaciji z docetakselom po kemoterapiji z doksorubicinom in ciklofosfamidom (AC → DH) ali v kombinaciji z docetakselom in karboplatinom
- intravenous docetaxel - 75 mg/m2 as an intravenous infusion over 1 hour, given every 3 weeks for 6 cycles (day 2 of cycle 1, then day 1 of each subsequent cycle) which was followed by: - carboplatin - at target AUC = 6 mg/mL/min administered by intravenous infusion over 3060 minutes repeated every 3 weeks for a total of six cycles
Odmerjanje paklitaksela v kombinaciji z zdravilom Herceptin je bilo naslednje: paklitaksel intravensko - 80 mg/m2 v obliki kontinuirane intravenske infuzije, vsak teden, skupaj 12 tednov ali paklitaksel intravensko - 175 mg/m2 v obliki kontinuirane intravenske infuzije, vsake 3 tedne, skupaj 4 cikle (na 1. dan vsakega cikla).
• chest pain
· vnetje jeter
Malignant neoplasm progression
napredovanje maligne neoplazme neznano napredovanje neoplazme neznano
Herceptin and anthracyclines should not be given concurrently in combination in the adjuvant treatment setting.
Metastatski rak dojk Pri zdravljenju metastatskega raka dojk kombinacije zdravila Herceptin in antraciklinov ne smemo dajati sočasno.
Uncommon side effects of Herceptin: may affect up to 1 in 100 people:
Pogosti neželeni učinki zdravila Herceptin, ki se lahko pojavijo pri največ 1 od 10 bolnikov, so:
Table 10 Overview of Efficacy Analyses BCIRG 006 AC→D versus DCarbH Parameter
Preglednica 10: Pregled analiz učinkovitosti za preskušanje BCIRG 006; AC → D v primerjavi
Hazard Ratio versus Observation *Co-primary endpoint of DFS of 1 year versus observation met the pre-defined statistical boundary **Final analysis (including crossover of 52 % of patients from the observation arm to Herceptin) *** There is a discrepancy in the overall sample size due to a small number of patients who were randomized after the cut-off date for the 12-month median follow-up analysis
***V celokupni velikosti vzorca je neskladje zaradi majhnega števila bolnikov, ki so jih randomizirali po preteku datuma, do katerega so upoštevali podatke za analizo po mediano 12-mesečnem spremljanju.
• hair loss
· kožni izpuščaj
At the time of the definitive analysis of DFS.
* V času končne analize preživetja brez bolezni.
Neutralizing antitrastuzumab antibodies were detected in post-baseline samples in 2 of 30 patients in the Herceptin intravenous arm and 3 of 47 in the Herceptin subcutaneous arm. 21.0 % of patients treated with Herceptin subcutaneous formulation developed antibodies against the excipient hyaluronidase (rHuPH20).
Pri 21,0 % bolnikov, zdravljenih s subkutano obliko zdravila Herceptin, so se pojavila protitelesa proti pomožni snovi hialuronidazi (rHuPH20).
• abnormal or impaired blood clotting • anaphylactic reactions
· okužbe · driska · zaprtje · zgaga (dispepsija) · utrujenost
Therefore, no constant value for half-life of trastuzumab can be deduced.
očitnega vpliva na očistek trastuzumaba niso opazili.
A: doxorubicin; C: cyclophosphamide; P: paclitaxel; H: trastuzumab DFS analysis was also performed at the final analysis of OS from the joint analysis of studies
A: doksorubicin; C: ciklofosfamid; P: paklitaksel; D: docetaksel; Carb: karboplatin; H: trastuzumab IZ = interval zaupanja * V času končne analize preživetja brez bolezni.
For intravenous use only
Za intravensko uporabo le po rekonstituciji in razredčitvi
Rhinitis
SERIJ
• respiratory failure
· motnje delovanja pljuč
No. patients with event p=0.0024
Smrt (dogodek celokupnega preživetja): število bolnikov z dogodkom p = 0,0024
Refer to the Summary of Product Characteristics (SmPC) for paclitaxel, docetaxel or aromatase inhibitor for information on dose reduction or delays.
Za zmanjšanje odmerka ali odlog dajanja paklitaksela, docetaksela ali zaviralca aromataze glejte njihove Povzetke glavnih značilnosti zdravila.
or
dan
The results of this substudy suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was not affected by concurrent use of cisplatin or by concurrent use of cisplatin plus Herceptin.
Herceptin ni vplivala na izpostavljenost biološko aktivnim metabolitom kapecitabina (npr. 5-FU).
Table 8 Final Overall Survival Analysis from the joint analysis of trials NSABP B-31 and NCCTG N9831
Končna analiza celokupnega preživetja iz skupne analize preskušanj NSABP B-31 in
The recommended scoring system to evaluate the IHC staining patterns is as stated in Table 2: Table 2 Recommended Scoring System to Evaluate the IHC Staining Patterns in Breast Cancer Score Staining pattern
Priporočeno točkovanje za vrednotenje obarvanja preparatov po metodi IHC pri raku dojk Rezultat
Rare side effects of Herceptin: may affect up to 1 in 1,000 people
Redki neželeni učinki zdravila Herceptin, ki se lahko pojavijo pri največ 1 od 1000 bolnikov, so: · mišična šibkost · zlatenica
Roche Pharma AG Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany
Roche Pharma AG Emil-Barell-Strasse-1
• Hypertension: 4.7 % versus 9.8 % for the intravenous formulation versus subcutaneous formulation respectively.
14,1 % za intravensko obliko v primerjavi z 21,5 % za subkutano obliko.
Table 4: Efficacy results from the non-comparative monotherapy and combination therapy studies Parameter
Preglednica 4 navaja rezultate učinkovitosti monoterapije in kombiniranega zdravljenja iz študij brez primerjalne skupine.
* At median duration of follow up of 1.8 years for the patients in the AC→P arm and 2.0 years for patients in the AC→PH arm ** p value for OS did not cross the pre-specified statistical boundary for comparison of AC→PH vs. AC→P
** Vrednost p za celokupno preživetje ni presegla vnaprej določene statistične meje za primerjavo AC → PH z
• dizziness
· pasasti izpuščaj
If you receive Herceptin with any other medicine to treat cancer, such as paclitaxel, docetaxel, an aromatase inhibitor, carboplatin or cisplatin you should also read the patient information leaflets for these products.
zaviralec aromataze, karboplatin ali cisplatin, preberite tudi navodila za uporabo teh zdravil.
- The NSABP B-31 and NCCTG N9831 studies that comprise the joint analysis were designed to investigate the clinical utility of combining Herceptin treatment with paclitaxel following AC chemotherapy, additionally the NCCTG N9831 study also investigated adding Herceptin sequentially to AC→P chemotherapy in patients with HER2 positive EBC following surgery.
Dodatno so v preskušanju NCCTG N9831 pri bolnikih z zgodnjo obliko HER2-pozitivnega raka dojk po operaciji proučevali zaporedno dajanje zdravila Herceptin po kemoterapiji z doksorubicinom in ciklofosfamidom, ki jima je sledil paklitaksel (kemoterapiji AC → P).
The median overall survival for the high HER2 expressing group was 11.8 months versus 16 months, HR 0.65 (95 % CI 0.51-0.83) and the median progression free survival was 5.5 months versus 7.6 months, HR 0.64 (95 % CI 0.51-0.79) for FP versus FP + H, respectively.
Mediana celokupnega preživetja v skupini, ki je imela visoko izražen HER2, je bila 11,8 meseca za skupino, ki ni prejemala zdravila Herceptin, v primerjavi s 16 meseci za skupino, ki je prejemala tudi zdravilo Herceptin - razmerje ogroženosti 0,65 (95-% interval zaupanja; 0,51-0,83).
Renal failure
Neželeni učinek
Ear and labyrinth disorders Deafness
Ušesne bolezni, vključno z motnjami labirinta gluhost občasno
Back pain
· bolečina v hrbtu
As a weekly regimen (initial loading dose of 4 mg/kg followed by 2 mg/kg every week) concomitantly with paclitaxel following chemotherapy with doxorubicin and cyclophosphamide.
Pri tedenskem režimu (uvajalni odmerek 4 mg/kg telesne mase, nato 2 mg/kg telesne mase vsak teden)
• hot flush
· vročinski oblivi
The recommended scoring system to evaluate the IHC staining patterns is as stated in Table 2: Table 2: Recommended scoring system to evaluate the IHC staining patterns Score Staining pattern
Priporočeni način vrednotenja rezultatov obarvanja preparatov po metodi IHC je naveden v preglednici 2.
No reactivity or membranous reactivity in < 10 % of tumour cells
bazolateralne ali lateralne membrane pri > 10 % tumorskih celic.
barely perceptible membranous reactivity irrespective of percentage of tumour cells stained
Klaster tumorskih celic ima bledo, komaj zaznavno obarvanje membrane, neglede na odstotek obarvanih tumorskih celic.
- intravenous docetaxel - 100 mg/m2 as an intravenous infusion over 1 hour, given every 3 weeks for 4 cycles (day 2 of first docetaxel cycle, then day 1 of each subsequent cycle)
Odmerjanje docetaksela je bilo naslednje: - docetaksel intravensko - 100 mg/m2 v obliki intravenske infuzije v 1 uri, vsake 3 tedne, skupaj 4
- as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease.
Zdravilo Herceptin je indicirano za zdravljenje odraslih bolnikov s HER2-pozitivno metastatsko obliko raka dojk: - kot monoterapija za zdravljenje tistih bolnikov, ki so za svojo metastatsko bolezen predhodno že prejemali najmanj dve liniji kemoterapije.
weeks for 6 cycles (day 2 of cycle 1, then day 1 of each subsequent cycle) which was followed by: - carboplatin - at target AUC = 6 mg/mL/min administered by intravenous infusion over 3060 minutes repeated every 3 weeks for a total of six cycles
Odmerjanje doksorubicina in ciklofosfamida, ki so ju dajali sočasno, je bilo naslednje: doksorubicin v obliki intravenskega bolusa - 60 mg/m2, vsake 3 tedne, 4 cikle; ciklofosfamid intravensko - 600 mg/m2 v 30 minutah, vsake 3 tedne, 4 cikle.
Glomerulonephritis membranous
L-histidinijev klorid monohidrat
Herceptin Subcutaneous
zdravilo Herceptin2
In this leaflet:
so:
If the patient misses a dose of Herceptin subcutaneous formulation, it is recommended to administer the next 600 mg dose (i.e. the missed dose) as soon as possible.
Če je bolnik izpustil odmerek zdravila Herceptin v subkutani obliki, mu je treba dati naslednji
Time to Disease Progression,
Motnje v času nosečnosti,
Polysorbate 20
L-metionin polisorbat 20 voda za injekcije
Herceptin Intravenous
Intravenska oblika zdravila Herceptin
Some adverse events / reactions were reported with a higher frequency for the subcutaneous formulation:
O nekaterih neželenih učinkih so poročali pogosteje pri subkutani obliki: · resni neželeni učinki (večino od teh so odkrili zaradi hospitalizacije ali njenega podaljšanja):
Invented name StrengthPharmaceutical form
Izmišljeno ime Jakost Farmacevtska oblika
This overview was last updated in June 2018.
Pregled je bil nazadnje posodobljen junija 2018.
Further information on Nobivac LeuFel can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Nadaljnje informacije o zdravilu Nobivac LeuFel so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
This medicine is the same as Leucogen, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Leucogen, ki je že odobreno v Evropski uniji (EU).
The FeLV protein used in the vaccine is not extracted from viruses but is made in a bacterium using ‘recombinant technology'.
Beljakovina FeLV, uporabljena v cepivu, ni pridobljena iz virusov, pač pa je bila narejena v bakteriji s pomočjo „rekombinantne tehnologije“.
The vaccine is used to prevent the disease signs and persistent viraemia (the presence of FeLV in the blood).
Cepivo se uporablja za preprečevanje znakov bolezni in trajne viremije (prisotnosti virusa FeLV v krvi).
The European Medicines Agency decided that Nobivac LeuFel's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je odločila, da so koristi zdravila Nobivac LeuFel večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The vaccine is given to cats as an injection under the skin.
Cepivo se mačkam daje z injiciranjem pod kožo.
The most common side effects with Nobivac LeuFel (which may affect up to 1 in 10 cats) are a moderate and short-lived local reaction (≤2 cm) after the first injection which resolves without treatment within 3 to 4 weeks, raised body temperature (lasting 1 to 4 days), apathy (listlessness) and digestive disturbances.
Najpogostejši neželeni učinki zdravila Nobivac LeuFel (ki lahko prizadenejo največ 1 mačko od 10) so zmerna in kratkotrajna lokalna reakcija (≤ 2 cm) po prvi injekciji, ki izzveni v treh do štirih tednih brez zdravljenja, povišana telesna temperatura (ki traja od enega do štirih dni), apatija (ravnodušnost) in prebavne motnje.
Nobivac LeuFel received a marketing authorisation valid throughout the EU for Nobivac LeuFel on 6 November 2017.
Zdravilo Nobivac LeuFel je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 6. novembra 2017.
This authorisation was based on the authorisation granted to Leucogen in 2009 (‘informed consent').
Izdaja tega dovoljenja je temeljila na dovoljenju za promet z zdravilom Leucogen, ki je bilo izdano leta 2009 (uporaba dokumentacije s soglasjem).
Nobivac LeuFel is a vaccine.
Zdravilo Nobivac LeuFel je cepivo.
Following the first booster vaccination, protection lasts 3 years.
Po prvem obnovitvenem cepljenju traja zaščita tri leta.
In the future, the immune system will be able to produce antibodies more quickly when it is exposed to FeLV, which will help to protect against the disease caused by the virus.
Ob ponovni izpostavljenosti virusu FeLV v prihodnosti bo imunski sistem lahko protitelesa tvoril hitreje, kar pomaga pri zaščiti pred boleznijo, ki jo virus povzroča.
For the full list of restrictions and all side effects reported with Nobivac LeuFel, see the package leaflet.
Za celoten seznam omejitev in neželenih učinkov, o katerih so poročali pri uporabi zdravila Nobivac LeuFel, glejte navodilo za uporabo.
Feline leukaemia is an infectious disease of cats which affects the immune system and is caused by the feline leukaemia virus (FeLV).
Mačja levkemija je nalezljiva bolezen mačk, ki vpliva na imunski sistem in jo povzroča virus mačje levkemije (FeLV).
In cases where the kitten may have antibodies passed from the mother, a third injection can be given from 15 weeks of age.
Če je mlada mačka od matere prejela protitelesa, lahko tretjo injekcijo prejme od starosti 15 tednov dalje.
A laboratory study in which cats were exposed to feline leukaemia virus confirmed that following the first annual booster vaccination cats were protected for a three year period against leukaemia.
Laboratorijska študija, v kateri so bile mačke izpostavljene virusu mačje levkemije, je potrdila, da so mačke po prvem letnem obnovitvenem cepljenju pred levkemijo zaščitene tri leta.
The company that makes Leucogen has agreed that its scientific data can be used for Nobivac LeuFel (‘informed consent').
Podjetje, ki proizvaja zdravilo Leucogen, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Nobivac LeuFel („uporaba dokumentacije s soglasjem“).
Other information about Nobivac LeuFel
Druge informacije o zdravilu Nobivac LeuFel
Why is Nobivac LeuFel authorised in the EU?
Zakaj je zdravilo Nobivac LeuFel odobreno v EU?
What is Nobivac LeuFel and what is it used for?
Kaj je zdravilo Nobivac LeuFel in za kaj se uporablja?
Nobivac LeuFel must not be used in pregnant cats.
Zdravilo Nobivac LeuFel se ne sme uporabljati pri brejih mačkah.
The initial vaccination course is two injections 3 or 4 weeks apart from 8 weeks of age.
Prvi sklop cepljenja vključuje dve injekciji s tri- ali štiritedenskim razmikom pri starosti nad osem tednov.
An overview of Nobivac LeuFel and why it is authorised in the EU
Pregled zdravila Nobivac LeuFel in zakaj je odobreno v EU
When a cat is given the vaccine, the cat's immune system recognises the protein as ‘foreign' and makes antibodies against it.
Ko mačka prejme cepivo, imunski sistem prepozna beljakovino kot tujek in proti njej tvori protitelesa.
In a second study, kittens aged 8 to 9 weeks were given an initial vaccination course of a combination vaccine consisting of one dose of Feligen RCP (against feline rhinotracheitis virus, feline calici virus and feline panleucopaenia virus) with one dose of Nobivac LeuFel.
V drugi študiji so mlade mačke, stare od osem do devet tednov, prejele začetni sklop cepljenja s kombiniranim cepivom, ki je vsebovalo en odmerek zdravila Feligen RCP (cepiva proti virusu mačjega rinotraheitisa, mačjemu kalicivirusu in virusu mačje panlevkopenije) in en odmerek zdravila Nobivac LeuFel.
Protection starts 3 weeks after the primary course of vaccination and lasts one year.
Zaščita je učinkovita od tretjega tedna po prvem sklopu cepljenja in traja eno leto.
What are the risks associated with Nobivac LeuFel?
Kakšna tveganja so povezana z zdravilom Nobivac LeuFel?
Nobivac LeuFel is available as a suspension for injection and can only be obtained with a prescription.
Zdravilo Nobivac LeuFel je na voljo v obliki suspenzije za injiciranje, predpisovanje in izdaja zdravila pa je le na recept.